B. Aygen, “Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience”, Turkish Journal of Gastroenterology, vol. 31, no. 4, pp. 305–317, Jan. 2020.